Episode Details

On this episode we feature the CEO of Bionyra, Frederic Marrache, after closing French-biotech's largest ever Series A ($165million) this summer.

Bionyra are a Sofinnova-incubated I&I biotech advancing in-licensed monoclonal (TL1A & IL25) & bispecific (TL1AxIL-23p19) HLE antibodies for a range of autoimmune indications. In this conversation we discuss why, after a decade within Sanofi's I&I development organisation, Frederic viewed the Bionyra opportunity as 'the one' to scratch his biotech itch.

Naturally, we then discuss the promise of their technology which led to the likes of Jeito & Sanofi's CVC to participate in their record breaking Series A. Frederic also discusses indication expansion possibilities, and an upcoming 18-24 months that promise to be milestone-rich.

One to check-out for anyone interested in immunology drug-development and particularly those with an eye on company building in Europe.